Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat Med. 2017 Apr; 23(4):472-482.
View in:
PubMed
subject areas
Adult
Animals
Apoptosis
Blotting, Western
Cell Proliferation
Drug Resistance, Neoplasm
Dual Specificity Phosphatase 1
Female
Flow Cytometry
Gene Expression Profiling
Genes, abl
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Mice
Mice, Knockout
Mice, Transgenic
Middle Aged
Neoplasm Transplantation
Neoplasm, Residual
Neoplasms, Experimental
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-fos
Real-Time Polymerase Chain Reaction
Tumor Stem Cell Assay
authors with profiles
Ming Xu